Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2015 1
2016 2
2017 2
2018 2
2019 3
2020 3
2021 1
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC. Fribbens C, et al. J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269946 Clinical Trial.
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.
Turkes F, Bryant A, Begum R, Davidson M, Kalaitzaki E, Aresu M, Lazaro-Alcausi R, Bryant J, Rana I, Chua S, Aronson L, Hulkki-Wilson S, Fribbens C, Watkins D, Rao S, Starling N, Cunningham D, Chong IY, Chau I. Turkes F, et al. Among authors: fribbens c. Curr Oncol. 2022 Mar 22;29(4):2174-2184. doi: 10.3390/curroncol29040176. Curr Oncol. 2022. PMID: 35448150 Free PMC article.
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK, Fong C, Arouri F, Cortez L, Katifi H, Gonzalez-Exposito R, Razzaq MB, Li S, Macklin-Doherty A, Hernandez MA, Hubank M, Fribbens C, Watkins D, Rao S, Chau I, Cunningham D, Starling N. Lau DK, et al. Among authors: fribbens c. BMC Cancer. 2023 Apr 26;23(1):380. doi: 10.1186/s12885-023-10857-8. BMC Cancer. 2023. PMID: 37101114 Free PMC article.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. de Bruyn G, et al. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37533419 Free PMC article.
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Au L, Fendler A, Shepherd STC, Rzeniewicz K, Cerrone M, Byrne F, Carlyle E, Edmonds K, Del Rosario L, Shon J, Haynes WA, Ward B, Shum B, Gordon W, Gerard CL, Xie W, Joharatnam-Hogan N, Young K, Pickering L, Furness AJS, Larkin J, Harvey R, Kassiotis G, Gandhi S; Crick COVID-19 Consortium; Swanton C, Fribbens C, Wilkinson KA, Wilkinson RJ, Lau DK, Banerjee S, Starling N, Chau I; CAPTURE Consortium; Turajlic S. Au L, et al. Among authors: fribbens c. Nat Med. 2021 Aug;27(8):1362-1366. doi: 10.1038/s41591-021-01387-6. Epub 2021 May 26. Nat Med. 2021. PMID: 34040262 Free PMC article.
SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy.
Lau DK, Aresu M, Planche T, Tran A, Lazaro-Alcausi R, Duncan J, Kidd S, Cromarty S, Begum R, Rana I, Li S, Suwaidan AA, Monahan I, Clark DJ, Eckersley N, Staines HM, Groppelli E, Krishna S, Mayora-Neto M, Temperton N, Fribbens C, Watkins D, Starling N, Chau I, Cunningham D, Rao S. Lau DK, et al. Among authors: fribbens c. Oncologist. 2023 Jan 18;28(1):e1-e8. doi: 10.1093/oncolo/oyac230. Oncologist. 2023. PMID: 36342104 Free PMC article.
ESR1 mutations in metastatic lobular breast cancer patients.
Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, O'Leary B, van den Eynden G, Salgado R, Turner NC, Piccart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C. Desmedt C, et al. Among authors: fribbens c. NPJ Breast Cancer. 2019 Feb 22;5:9. doi: 10.1038/s41523-019-0104-z. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 30820448 Free PMC article.
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients.
Lote H, Mousoullou F, Vlachogiannis G, Lampis A, Satchwell L, Peckitt C, Fong C, Begum R, Kidd S, Cromarty S, Gordon A, Fribbens C, Rao S, Starling N, Chau I, Cunningham D, Valeri N. Lote H, et al. Among authors: fribbens c. Front Oncol. 2023 Nov 29;13:1258365. doi: 10.3389/fonc.2023.1258365. eCollection 2023. Front Oncol. 2023. PMID: 38094609 Free PMC article.
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M. Martin LA, et al. Among authors: fribbens c. Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y. Nat Commun. 2017. PMID: 29192207 Free PMC article.
21 results